INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Directory07Corporate Insiders08Government Money09Political Influence10Institutions11Washington Network12Follow the Power13Disclosure Clock14AI Investigator15Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
01Overview02Follow the Money03Daily Brief04Live05Congress06Directory07Corporate Insiders08Government Money09Political Influence10Institutions11Washington Network12Follow the Power13Disclosure Clock14AI Investigator15Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources
SEC FORM 43h ago
HOUSE PTR3h ago
SEC 13F3h ago
ROBINHOOD CHAIN3h ago
Public company

EBSEmergent BioSolutions Inc.

CIK 0001367644

EDGAR filingsOpen in network
Disclosed transactions27
Buys / sells0 / 0
Max Insider Score23
Connections11with evidence

EBS · disclosed activity on price

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
9
GC
Glessner ColeenEVP, Quality & Ethics, and CPL
EBSEmergent BioSolutions Inc.
Tax withholding
F$16K
2,018 sh
Jun 8, 2026Jun 10, 2026
traded Jun 8, 2026
+2dSEC FORM 4

Evidence

Verified connections

  • In industryevidence
    Pharmaceuticals, devices & health servicesSEC SIC 2834 · Pharmaceutical Preparations · Nov 4, 2026
  • ← Connected organizationevidence
    EMERGENT BIOSOLUTIONS INC. EMPLOYEES PACFEC Form 1 connected organization: EMERGENT BIOSOLUTIONS INC. (exact legal-name match) · Nov 4, 2026
  • ← Lobbied forevidence
    CGCN GROUP, LLCLDA Q2 2026 second quarter · DIS, Health issues, Homeland security, Budget/appropriations · Aug 26, 2026
  • ← Lobbied forevidence
    EMERGENT BIOSOLUTIONS INC.LDA Q1 2026 first quarter · Homeland security, DIS, Budget/appropriations, Health issues · Aug 26, 2026
  • ← Lobbied for
9
HW
Hartzel WilliamSVP, Bioservices
EBSEmergent BioSolutions Inc.
Tax withholding
F
$14K
1,741 sh
Jun 8, 2026
Jun 10, 2026
traded Jun 8, 2026
+2d
SEC FORM 4

Evidence

9
WA
Williams Paul AnthonySVP, Products Business
EBSEmergent BioSolutions Inc.
Tax withholding
F$5,552
694 sh
Jun 8, 2026Jun 10, 2026
traded Jun 8, 2026
+2dSEC FORM 4

Evidence

21
GC
Glessner ColeenEVP, Quality & Ethics, and CPL
EBSEmergent BioSolutions Inc.
Grant or award
A—
100.1K sh
Apr 29, 2026May 1, 2026
traded Apr 29, 2026
+2dSEC FORM 4

Evidence

21
PJ
Perl JessicaSVP, General Counsel, Corp Sec
EBSEmergent BioSolutions Inc.
Grant or award
A—
104.3K sh
Apr 29, 2026May 1, 2026
traded Apr 29, 2026
+2dSEC FORM 4

Evidence

21
HW
Hartzel WilliamSVP, Bioservices
EBSEmergent BioSolutions Inc.
Grant or award
A—
100.1K sh
Apr 29, 2026May 1, 2026
traded Apr 29, 2026
+2dSEC FORM 4

Evidence

21
LC
Lowry Simon CSVP, R&D, CMO
EBSEmergent BioSolutions Inc.
Grant or award
A—
100.1K sh
Apr 29, 2026May 1, 2026
traded Apr 29, 2026
+2dSEC FORM 4

Evidence

21
WA
Williams Paul AnthonySVP, Products Business
EBSEmergent BioSolutions Inc.
Grant or award
A—
100.1K sh
Apr 29, 2026May 1, 2026
traded Apr 29, 2026
+2dSEC FORM 4

Evidence

17
HW
Hartzel WilliamSVP, Bioservices
EBSEmergent BioSolutions Inc.
Grant or award
A—
44.8K sh
Mar 3, 2026Mar 5, 2026
traded Mar 3, 2026
+2dSEC FORM 4

Evidence

17
WA
Williams Paul AnthonySVP, Products Business
EBSEmergent BioSolutions Inc.
Grant or award
A—
44.8K sh
Mar 3, 2026Mar 5, 2026
traded Mar 3, 2026
+2dSEC FORM 4

Evidence

16
GC
Glessner ColeenEVP, Quality & Ethics, and CPL
EBSEmergent BioSolutions Inc.
Tax withholding
F$69K
8,199 sh
Mar 5, 2026Mar 5, 2026
traded Mar 5, 2026
+0dSEC FORM 4

Evidence

13
GC
Glessner ColeenEVP, Quality & Ethics, and CPL
EBSEmergent BioSolutions Inc.
Grant or award
A—
44.8K sh
Mar 3, 2026Mar 5, 2026
traded Mar 3, 2026
+2dSEC FORM 4

Evidence

16
LC
Lowry Simon CSVP, R&D, CMO
EBSEmergent BioSolutions Inc.
Tax withholding
F$90K
10.6K sh
Mar 5, 2026Mar 5, 2026
traded Mar 5, 2026
+0dSEC FORM 4

Evidence

17
LC
Lowry Simon CSVP, R&D, CMO
EBSEmergent BioSolutions Inc.
Grant or award
A—
44.8K sh
Mar 3, 2026Mar 5, 2026
traded Mar 3, 2026
+2dSEC FORM 4

Evidence

16
PJ
Perl JessicaSVP, General Counsel, Corp Sec
EBSEmergent BioSolutions Inc.
Tax withholding
F$55K
6,465 sh
Mar 5, 2026Mar 5, 2026
traded Mar 5, 2026
+0dSEC FORM 4

Evidence

17
PJ
Perl JessicaSVP, General Counsel, Corp Sec
EBSEmergent BioSolutions Inc.
Grant or award
A—
46.7K sh
Mar 3, 2026Mar 5, 2026
traded Mar 3, 2026
+2dSEC FORM 4

Evidence

16
HW
Hartzel WilliamSVP, Bioservices
EBSEmergent BioSolutions Inc.
Tax withholding
F$80K
9,493 sh
Mar 5, 2026Mar 5, 2026
traded Mar 5, 2026
+0dSEC FORM 4

Evidence

16
WA
Williams Paul AnthonySVP, Products Business
EBSEmergent BioSolutions Inc.
Tax withholding
F$79K
9,397 sh
Mar 5, 2026Mar 5, 2026
traded Mar 5, 2026
+0dSEC FORM 4

Evidence

9
PJ
Perl JessicaSVP, General Counsel, Corp Sec
EBSEmergent BioSolutions Inc.
Tax withholding
F$10K
918 sh
Feb 9, 2026Feb 10, 2026
traded Feb 9, 2026
+1dSEC FORM 4

Evidence

9
HW
Hartzel WilliamSVP, Bioservices
EBSEmergent BioSolutions Inc.
Tax withholding
F$6,880
630 sh
Feb 6, 2026Feb 10, 2026
traded Feb 6, 2026
+4dSEC FORM 4

Evidence

23
GC
Glessner ColeenEVP, Quality & Ethics, and CPL
EBSEmergent BioSolutions Inc.
Disposition to issuer
D$315K
28.8K sh
Feb 6, 2026Feb 10, 2026
traded Feb 6, 2026
+4dSEC FORM 4

Evidence

9
GC
Glessner ColeenEVP, Quality & Ethics, and CPL
EBSEmergent BioSolutions Inc.
Tax withholding
F$31K
2,852 sh
Feb 6, 2026Feb 10, 2026
traded Feb 6, 2026
+4dSEC FORM 4

Evidence

16
HW
Hartzel WilliamSVP, Bioservices
EBSEmergent BioSolutions Inc.
Disposition to issuer
D$63K
5,771 sh
Feb 6, 2026Feb 10, 2026
traded Feb 6, 2026
+4dSEC FORM 4

Evidence

16
WA
Williams Paul AnthonySVP, Products Business
EBSEmergent BioSolutions Inc.
Disposition to issuer
D$95K
8,655 sh
Feb 6, 2026Feb 10, 2026
traded Feb 6, 2026
+4dSEC FORM 4

Evidence

9
WA
Williams Paul AnthonySVP, Products Business
EBSEmergent BioSolutions Inc.
Tax withholding
F$11K
1,022 sh
Feb 6, 2026Feb 10, 2026
traded Feb 6, 2026
+4dSEC FORM 4

Evidence

9
LC
Lowry Simon CSVP, R&D, CMO
EBSEmergent BioSolutions Inc.
Tax withholding
F$40K
3,543 sh
Dec 14, 2025Dec 16, 2025
traded Dec 14, 2025
+2dSEC FORM 4

Evidence

9
HW
Hartzel WilliamSVP, Bioservices
EBSEmergent BioSolutions Inc.
Tax withholding
F$6,637
610 sh
Nov 11, 2025Nov 13, 2025
traded Nov 11, 2025
+2dSEC FORM 4

Evidence

evidence
CAPITOL COUNSEL LLC
LDA Q2 2026 second quarter · Health issues · Aug 26, 2026
  • ← Lobbied forevidence
    THE NICKLES GROUP, LLCLDA Q2 2026 second quarter · Budget/appropriations, Health issues, Defense · Aug 26, 2026
  • ← Insider ofevidence
    Perl JessicaSVP, General Counsel, Corp Sec · Feb 10, 2026
  • ← Insider ofevidence
    Glessner ColeenEVP, Quality & Ethics, and CPL · Feb 10, 2026
  • ← Insider ofevidence
    Williams Paul AnthonySVP, Products Business · Feb 10, 2026
  • ← Insider ofevidence
    Lowry Simon CSVP, R&D, CMO · Dec 16, 2025
  • ← Insider ofevidence
    Hartzel WilliamSVP, Bioservices · Nov 13, 2025

    • Lobbying

    $1.56M reported · de-duplicated
    2026 Q2 $670K via firms2026 Q1 $890K via firms
    • THE NICKLES GROUP, LLC$40K2026 Q2 · posted Aug 26, 2026 · Budget/appropriations, Health issues, Defense
    • CGCN GROUP, LLC$70K2026 Q1 · posted Aug 26, 2026 · Health issues, Budget/appropriations, DIS, Homeland security
    • CAPITOL COUNSEL LLC$50K2026 Q1 · posted Aug 26, 2026 · Health issues
    • CGCN GROUP, LLC$70K2026 Q2 · posted Aug 26, 2026 · DIS, Health issues, Homeland security, Budget/appropriations
    • EMERGENT BIOSOLUTIONS INC.$730K2026 Q1 · posted Aug 26, 2026 · Homeland security, DIS, Budget/appropriations, Health issues
    • CAPITOL COUNSEL LLC$50K2026 Q2 · posted Aug 26, 2026 · Health issues
    • EMERGENT BIOSOLUTIONS INC.$510K2026 Q2 · posted Aug 26, 2026 · Budget/appropriations, Health issues, Homeland security, DIS
    • THE NICKLES GROUP, LLC$40K2026 Q1 · posted Aug 26, 2026 · Budget/appropriations, Health issues, Defense

    Connected PAC contributions

    FEC · direct to members
    • Pete AguilarD$8,000EMERGENT BIOSOLUTIONS INC. EMPLOYEES PAC
    • John R. MoolenaarR$3,500EMERGENT BIOSOLUTIONS INC. EMPLOYEES PAC
    • Lori TrahanD$3,000EMERGENT BIOSOLUTIONS INC. EMPLOYEES PAC
    • Brett GuthrieR$2,500EMERGENT BIOSOLUTIONS INC. EMPLOYEES PAC
    • Shelley Moore CapitoR$2,500EMERGENT BIOSOLUTIONS INC. EMPLOYEES PAC
  • Dan CrenshawR$2,500EMERGENT BIOSOLUTIONS INC. EMPLOYEES PAC
  • Richard HudsonR$2,500EMERGENT BIOSOLUTIONS INC. EMPLOYEES PAC
  • Bill CassidyR$2,000EMERGENT BIOSOLUTIONS INC. EMPLOYEES PAC
  • Roger MarshallR$1,250EMERGENT BIOSOLUTIONS INC. EMPLOYEES PAC
  • Andy HarrisR$1,000EMERGENT BIOSOLUTIONS INC. EMPLOYEES PAC
  • Gabe AmoD$1,000EMERGENT BIOSOLUTIONS INC. EMPLOYEES PAC
  • Addison P. McDowellR$1,000EMERGENT BIOSOLUTIONS INC. EMPLOYEES PAC